Nephritis remains the most common severe manifestation of systemic lupus erythematosus in which auto-antibodies mediate chronic inflammation and kidney damage. cAMP-phosphodiesterases regulate sodium excretion and inflammation in various tissues. How cAMP elevation can reduce systemic inflammation and suppress kidney inflammation and damage remains elusive. PDE4 signaling and cAMP metabolism were investigated along immune complex depositions in target tissues and kidney damage (histology). SLE disease progression is associated with changes in kidney PDE4 activity and expression. Moreover, lupus prone mice exhibit low kidney cAMP level which is associated to induction and relocation of nuclear and cytoskeleton PDE4 isoforms. Auto-antibodies-induced kidney damage was attested by mesangial proliferation and cellular infiltration. Interestingly, we reported that NCS 613 treatment decreases systemic auto-antibody secretion and their corresponding immune complex deposition in target tissues. Furthermore, NCS 613 is able to increase cAMP levels in the kidney; hence this compound rescues kidney PDE4 alterations in treated mice. NCS 613 overcomes disease progression in lupus prone mice by improving wellbeing and decreasing inflammation in treated mice. The PDE4 inhibitor, NCS 613, is a new anti-inflammatory compound that is believed to be a leading drug candidate for the treatment of inflammatory diseases such as lupus nephritis.

肾炎仍然是系统性红斑狼疮最常见的严重表现，其中自身抗体介导慢性炎症和肾脏损害。cAMP-磷酸二酯酶调节各种组织中的钠排泄和炎症。cAMP升高如何减少全身性炎症并抑制肾脏炎症和损害仍然难以捉摸。PDE4信号转导和cAMP代谢沿靶组织中免疫复合物沉积和肾脏损害进行了研究（组织学）。SLE疾病的进展与肾脏PDE4活性和表达的改变有关。此外，狼疮易感小鼠表现出较低的肾脏cAMP水平，这与核和细胞骨架PDE4亚型的诱导和迁移有关。自身抗体诱导的肾损伤通过系膜增生和细胞浸润证明。有趣的是 我们报道了NCS 613治疗可减少全身自身抗体的分泌及其在靶组织中的相应免疫复合物沉积。此外，NCS 613能够增加肾脏中的cAMP水平。因此，该化合物可挽救治疗小鼠的肾脏PDE4改变。NCS 613通过改善受治疗的小鼠的健康状况并减少其炎症，克服了狼疮易感小鼠的疾病进展。PDE4抑制剂NCS 613是一种新型抗炎化合物，被认为是治疗诸如狼疮性肾炎等炎性疾病的领先药物。因此，该化合物可挽救治疗小鼠的肾脏PDE4改变。NCS 613通过改善受治疗的小鼠的健康状况并减少其炎症，克服了狼疮易感小鼠的疾病进展。PDE4抑制剂NCS 613是一种新型抗炎化合物，被认为是治疗诸如狼疮性肾炎等炎性疾病的领先药物。因此，该化合物可挽救治疗小鼠的肾脏PDE4改变。NCS 613通过改善受治疗的小鼠的健康状况并减少其炎症，克服了狼疮易感小鼠的疾病进展。PDE4抑制剂NCS 613是一种新型抗炎化合物，被认为是治疗诸如狼疮性肾炎等炎性疾病的领先药物。